Quotes are at least 15-min delayed:2026/01/05 08:53 EST
Pre Market
|
||||
|
7.56 
|
|
|
Regular Hours (Closed)
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
0.02/-0.95
|
|
Enterprise Value
2.90B
|
| Balance Sheet |
|
Book Value Per Share
1.26
|
| Cash Flow |
|
Cash Flow Yield
0.01
|
| Income Statement |
|
Total Revenue
783.21M
|
|
Operating Revenue Per Share
--
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |
